HK1023943A1 - Medicament for the treatment of diabetes mellitus as well as its subsequent disorders - Google Patents

Medicament for the treatment of diabetes mellitus as well as its subsequent disorders

Info

Publication number
HK1023943A1
HK1023943A1 HK00103082A HK00103082A HK1023943A1 HK 1023943 A1 HK1023943 A1 HK 1023943A1 HK 00103082 A HK00103082 A HK 00103082A HK 00103082 A HK00103082 A HK 00103082A HK 1023943 A1 HK1023943 A1 HK 1023943A1
Authority
HK
Hong Kong
Prior art keywords
diabetes mellitus
medicaments
medicament
treatment
well
Prior art date
Application number
HK00103082A
Other languages
English (en)
Inventor
Klaus Wessel
Harald Borbe
Heinz Ulrich
Helmut Hettche
Hans Bisswanger
Lester Packer
Amira Klip
Original Assignee
Viatris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6505606&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1023943(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viatris Gmbh filed Critical Viatris Gmbh
Publication of HK1023943A1 publication Critical patent/HK1023943A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK00103082A 1993-12-21 2000-05-24 Medicament for the treatment of diabetes mellitus as well as its subsequent disorders HK1023943A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4343593A DE4343593C2 (de) 1993-12-21 1993-12-21 Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz

Publications (1)

Publication Number Publication Date
HK1023943A1 true HK1023943A1 (en) 2000-09-29

Family

ID=6505606

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00103082A HK1023943A1 (en) 1993-12-21 2000-05-24 Medicament for the treatment of diabetes mellitus as well as its subsequent disorders

Country Status (11)

Country Link
US (4) US5693664A (el)
EP (2) EP0958816B1 (el)
JP (1) JPH07206676A (el)
AT (2) ATE203669T1 (el)
CA (1) CA2138558C (el)
DE (3) DE4343593C2 (el)
DK (2) DK0958816T3 (el)
ES (2) ES2258302T3 (el)
GR (1) GR3036943T3 (el)
HK (1) HK1023943A1 (el)
PT (2) PT659408E (el)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4343593C2 (de) * 1993-12-21 1998-05-20 Asta Medica Ag Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz
DE4433764A1 (de) * 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
US6752999B2 (en) 1995-09-20 2004-06-22 Nicholas V. Perricone Method of skin care and/or treatment using lipoic acid
US7438896B2 (en) * 1995-09-20 2008-10-21 N.V. Perricone Llc Method of skin care using lipoic and ascorbic acids
WO1998023606A1 (fr) * 1996-11-27 1998-06-04 Fuji Kagaku Kogyo Kabushiki Kaisha Derives dithio cycliques, remedes contre des maladies renales diabetiques, agents hypoglycemiques, agents hypolipidemiques et agents lenitifs contre les troubles digestifs
EP0855396A1 (en) * 1997-01-22 1998-07-29 ASTA Medica Aktiengesellschaft Thioctic acid metabolites and methods of use thereof
DE19705555A1 (de) * 1997-02-13 1998-08-20 Ulrich Dr Posanski Pharmazeutische Präparate der Thioctsäure zur oralen Anwendung
IL123887A0 (en) * 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
US6472432B1 (en) 1997-11-17 2002-10-29 Nicholas V. Perricone Treatment of rosacea using lipoic acid
US6365623B1 (en) 1997-11-17 2002-04-02 Nicholas V. Perricone Treatment of acne using lipoic acid
US5965618A (en) * 1997-11-17 1999-10-12 Perricone; Nicholas V. Treatment of scar tissue using lipoic acid
DE19806354B4 (de) * 1998-02-10 2004-09-16 Bdd Group Holding Ag Verwendung von α-Liponsäure oder deren physiologisch verträgliche Salze zur Behandlung von LDL-Hypercholesterinämie
US6090842A (en) * 1998-03-10 2000-07-18 The Regents Of The University Of California Lipoic acid analogs
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US20040259895A1 (en) * 1998-05-28 2004-12-23 Medical Research Institute Oral formulation of lipid soluble thiamine and lipoic acid
US20050085498A1 (en) * 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
US6905707B2 (en) * 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
US20060024367A1 (en) * 1998-05-28 2006-02-02 Byrd Edward A Controlled release alpha lipoic acid formulation with an inositol compound
US6191162B1 (en) 1998-05-28 2001-02-20 Medical Research Institute Method of reducing serum glucose levels
JP2000169371A (ja) * 1998-10-02 2000-06-20 Sankyo Co Ltd ジチオラン誘導体を含有する医薬
US20010041187A1 (en) * 1998-10-20 2001-11-15 Carl W Hastings Performance-enhancing dietary supplement
US6288106B1 (en) * 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
WO2000072854A1 (en) * 1999-06-02 2000-12-07 Ashni Naturaceuticals, Inc. A dietary supplement containing vanadyl sulfate, alpha-lipoic acid, and taurine
DE19954321A1 (de) * 1999-11-11 2001-07-26 Asta Medica Ag Erleichterte Verabreichung von alpha-Liponsäure oder Derivaten derselben
US6387945B2 (en) * 2000-04-11 2002-05-14 The Regents Of The University Of California Lipoic acid analogs
DK1294353T3 (da) * 2000-06-06 2006-07-10 Basf Ag Anvendelse af en (R) -enantiomer af liponsyre i kosmetiske og dermatologiske sammensætninger
EP1172110A3 (de) * 2000-07-07 2003-09-17 Basf Aktiengesellschaft Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen
DE10045059A1 (de) * 2000-09-12 2002-03-21 Basf Ag Therapeutische Kombination von Liponsäure und Konjuensäuren zur Behandlung diabetischer Störungen
DE10048531C1 (de) * 2000-09-30 2002-04-25 Porsche Ag Kühlluftführung für Kraftfahrzeuge
EP1339705B1 (de) 2000-11-30 2006-06-07 Basf Aktiengesellschaft Verfahren zur herstellung von liponsäure und dihydroliponsaüre
US6359075B1 (en) 2001-01-09 2002-03-19 Bridgestone/Firestone, Inc. Means of producing high diblock content thermoplastic elastomers via chain transfer
DE10113974B4 (de) * 2001-03-22 2008-05-29 Alzchem Trostberg Gmbh Verwendung von racemischer und enantiomerenreiner Dihydroliponsäure oder deren Derivate zur Körpergewichtsreduzierung und/oder zur Verringerung des Appetits
HUP0400732A3 (en) * 2001-04-30 2007-05-29 Trommsdorff Arzneimittel Pharmaceutically active uridine esters
DE10125882B4 (de) * 2001-05-28 2007-03-29 Esparma Gmbh Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus
DE10137381A1 (de) * 2001-07-31 2003-02-13 Viatris Gmbh Neue Modifikationen des Trometamolsalzes der R-Thioctsäure sowie Verfahren zu ihrer Herstellung
AU2002352726A1 (en) 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
WO2003084532A1 (en) * 2002-04-03 2003-10-16 Avery Mitchell A Lipoic acid analogs useful as provitamins and antioxidants
US6733793B2 (en) 2002-06-04 2004-05-11 Metaproteomics, Llc Oral composition with insulin-like activities and methods of use
US20050256178A1 (en) * 2002-08-23 2005-11-17 Eggersdorfer Manfred L Novel nutraceutical compositions comprising boitin
JP4716666B2 (ja) * 2003-05-21 2011-07-06 有限会社オガ リサーチ α−リポ酸含有水性製剤
ITMI20032528A1 (it) * 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il
WO2005095636A2 (en) * 2004-03-24 2005-10-13 Aveo Pharmaceuticals, Inc. Methods for measuring enzyme activities in cells, blood, tumors and tissues
DE102004050353A1 (de) * 2004-10-15 2006-04-20 Basf Ag Verwendung stabiler Ammoniumsalze der Liponsäure zur Behandlung diabetischer und weiterer Störungen
WO2006042666A1 (de) * 2004-10-18 2006-04-27 Meda Pharma Gmbh & Co. Kg R-(+)-α-LIPONSÄURE ZUR PRÄVENTION VON DIABETES
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
JP2006321732A (ja) * 2005-05-18 2006-11-30 Fancl Corp 異常蛋白質除去及び８−ヒドロキシ２’−デオキシグアノシン増加抑制用組成物
US20070055070A1 (en) * 2005-09-07 2007-03-08 Lawrence Lowell J Novel esters of lipoic acid
US20070083054A1 (en) * 2005-10-12 2007-04-12 Lawrence Lowell J Novel amides of lipoic acid
EP1984348A2 (en) * 2006-02-10 2008-10-29 Multi Formulations Ltd. Method for improving the oral administration of alpha-lipoic acid
US20070225354A1 (en) * 2006-03-21 2007-09-27 Eric Marchewitz Use of dihydrolipoamide for enhancing physical performance
JP2010520333A (ja) * 2007-03-01 2010-06-10 セダーズ−シナイ メディカル センター 〔１，２〕−ジチオラン部分を含有する抗酸化剤重合体およびその使用
DE102007038849A1 (de) 2007-08-16 2009-02-19 Adscil Gmbh Verwendung von R(+)-alpha-Liponsäure zur Behandlung der kryptogenen Neuropathie
US20090054513A1 (en) * 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
US7943163B2 (en) * 2007-08-22 2011-05-17 Response Scientific, Inc. Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
US9028874B2 (en) * 2008-01-03 2015-05-12 Cedars-Sinai Medical Center Antioxidant nanosphere comprising [1,2]-dithiolane moieties
CN102089276A (zh) * 2008-03-04 2011-06-08 罗伯特·绍尔 酶结构、活性和/或表达水平的调节
DE202008005023U1 (de) 2008-04-11 2008-07-17 Day-Med-Concept Gmbh Verwendung von α-Liponsäure und Coenzym Q10 zur selektiven Reduktion des visceralen Fettgewebes
EP2300451A1 (en) * 2008-06-02 2011-03-30 Cedars-Sinai Medical Center Nanometer-sized prodrugs of nsaids
US20100099751A1 (en) * 2008-10-21 2010-04-22 Al-Mulla Fahd Method of treating diabetes-related vascular complications
CN102245765B (zh) 2008-10-21 2015-01-07 通用医院公司 细胞移植
WO2010052310A1 (en) * 2008-11-07 2010-05-14 Segix Italia S.R.L. Alpha-lipoic acid derivatives and their use in drug preparation
KR101493125B1 (ko) 2008-11-24 2015-02-12 세다르스-신나이 메디칼 센터 항산화성 캠토테신 유도체 및 이들의 항산화성 항종양성 나노구체
KR100935554B1 (ko) 2009-06-24 2010-01-07 주식회사 셀트리온제약 피페라진 다이티옥트산염 및 이를 포함하는 약제학적 조성물
KR101208955B1 (ko) * 2010-06-01 2012-12-06 주식회사 셀트리온제약 피페라진 다이티옥트산염 및 글리메피리드를 포함하는 약제학적 조성물
CN103153376B (zh) 2010-08-06 2018-04-20 通用医院公司以麻省总医院名义经营 用于细胞处理相关应用的***和设备
WO2015001568A2 (en) * 2013-07-01 2015-01-08 Laurus Labs Private Limited Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof
FR3027228B1 (fr) * 2014-10-20 2016-12-09 Valbiotis Composition comprenant un melange d'extraits vegetaux et utilisation pour agir sur le metabolisme glucidique et/ou lipidique
CN115536631B (zh) * 2021-06-30 2024-01-30 江苏同禾药业有限公司 一种高纯度的右旋硫辛酸镁盐的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1213141B (it) * 1984-02-17 1989-12-14 Dobrivoje Tomic Composizioni farmaceutiche per il trattamento del diabete e di malattie e disfunzioni epatiche.
DE4218572A1 (de) * 1992-06-05 1993-12-09 Asta Medica Ag Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
DE4343593C2 (de) * 1993-12-21 1998-05-20 Asta Medica Ag Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz

Also Published As

Publication number Publication date
DE4343593A1 (de) 1995-06-22
DE4343593C2 (de) 1998-05-20
CA2138558A1 (en) 1995-06-22
PT958816E (pt) 2006-06-30
DE59409810D1 (de) 2001-09-06
ATE319444T1 (de) 2006-03-15
PT659408E (pt) 2001-12-28
DK0659408T3 (da) 2001-10-01
EP0958816A3 (de) 1999-12-15
US5693664A (en) 1997-12-02
EP0958816B1 (de) 2006-03-08
GR3036943T3 (en) 2002-01-31
CA2138558C (en) 2009-02-10
ES2159539T3 (es) 2001-10-16
ES2258302T3 (es) 2006-08-16
EP0659408A1 (de) 1995-06-28
JPH07206676A (ja) 1995-08-08
EP0958816A2 (de) 1999-11-24
EP0659408B1 (de) 2001-08-01
DE59410429D1 (de) 2006-05-04
US6117899A (en) 2000-09-12
DK0958816T3 (da) 2006-07-17
ATE203669T1 (de) 2001-08-15
US6284787B1 (en) 2001-09-04
US5948810A (en) 1999-09-07

Similar Documents

Publication Publication Date Title
HK1023943A1 (en) Medicament for the treatment of diabetes mellitus as well as its subsequent disorders
EP0334507A3 (en) Skin improving composition containing gamma-linolenic acid or dihomo-gamma-linolenic acid
EP0218460A3 (en) Use of gamma-linolenic acid and related compounds in the treatment of complications of diabetes mellitus
GR900300016T1 (en) A composition of matter for increasing intracellular atp levels and physical performance levels and for increasing the rate of wound repair
CA2029420A1 (en) Pharmaceutical compositions and methods for inhibition of maillard's reaction
CA2097732A1 (en) Composition comprising r-alpha-lipoic acid and vitamin e for treating diabetes mellitus
AU1923088A (en) Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
EP0465508A4 (en) Dietary supplement for insulin-resistant diabetics
ES2167338T3 (es) Composicion para tratar pacientes con enfermedades hepaticas.
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
NZ334269A (en) Use of GLP-1 and analogs in treatment of myocardial infarction
DK179286D0 (da) Insulinpraeparat
GR3003402T3 (en) Vanadium-peroxide compositions as insulin mimickers
MXPA05005848A (es) Uso de acidos alfa-feniltiocarboxilicos y alfa-feniloxicarboxilicos con actividad reductora de la glucosa en suero y reductora de lipidos en el suero.
NZ332105A (en) Medicaments including human growth hormone for the treatment of type II diabetes and metabolic syndrome
IL87566A0 (en) Medical composition for the treatment of diabetes comprising a benzamide derivative
AU617998B2 (en) Anticoccidial composition
AU2940992A (en) Immediate-effect flurbiprofen-containing medicament and its use
CA2030346A1 (en) Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
AU6432899A (en) Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
EP0228415A4 (en) INCREASE IN THE FLOW OF GLASS MOOD.
DE3812008C2 (el)
EP0334674A3 (en) Use of isoxazolinones as cerebro-active drugs
AU7719591A (en) Therapeutic agent
WO2003082283A3 (en) Pharmaceutical composition with combined active agents and methods for using the same

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20111217